TipRanks
Takeda Pharmaceutical Company (MX:TAKN)
:TAKN
Mexico Market
TAKN
Takeda Pharmaceutical Company
RESEARCH TOOLSreports

Takeda Pharmaceutical Company (TAKN) Stock News & Sentiment

0 Followers
Takeda’s GATTEX Safety Survey Update: What Investors Should Watch
Premium
Company Announcements
Takeda’s GATTEX Safety Survey Update: What Investors Should Watch
3h ago
TAK
Takeda Refines VPRIV Home Infusion Playbook With New EU Survey
Premium
Company Announcements
Takeda Refines VPRIV Home Infusion Playbook With New EU Survey
4d ago
TAK
Takeda’s OBIZUR Surveillance Study: Real World Data That Could Steady TAK’s Growth
Premium
Company Announcements
Takeda’s OBIZUR Surveillance Study: Real World Data That Could Steady TAK’s Growth
24d ago
TAK
Takeda Advances Pediatric Bleeding Disorder Program With New Vonicog Alfa Study Update
Premium
Company Announcements
Takeda Advances Pediatric Bleeding Disorder Program With New Vonicog Alfa Study Update
26d ago
TAK
Takeda Backs Real‑World Fruquintinib Study in Metastatic Colorectal Cancer
Premium
Company Announcements
Takeda Backs Real‑World Fruquintinib Study in Metastatic Colorectal Cancer
1M ago
TAK
Takeda’s Replagal Trial in India: Fresh Clinical Update With Rare Disease Upside
Premium
Company Announcements
Takeda’s Replagal Trial in India: Fresh Clinical Update With Rare Disease Upside
1M ago
TAK
Takeda’s Real-World CMV Study in Argentina Reaches Key Milestone
Premium
Company Announcements
Takeda’s Real-World CMV Study in Argentina Reaches Key Milestone
2M ago
TAK
More MX:TAKN News >

TAKN News on the Web

Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial
rttnews
Bullish
Innovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock Down
rttnews
Bullish
Innovent Biologics announces expansion of global Phase 3 MarsLight-11 trial
TipRanks News
Neutral
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
Zacks
Neutral
Takeda announces FDA acceptance of zasocitinib under priority review
TipRanks News
Bullish
Morgan Stanley Remains a Buy on Takeda Pharmaceutical Co (TKPHF)
TipRanks News
Bullish
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
TipRanks News
Neutral
Inventiva Names Chris Benecchi As COO Ahead Of Lanifibranor's Phase 3 Readout
rttnews
Neutral

News Score - Last 7 Days

Very Positive
MX:TAKN
Sector Average
Media Buzz
This Week7 articles
Weekly Average5.5 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

FAQ

What is MX:TAKN’s Media Buzz Sentiment?
7 articles about MX:TAKN were published this week. In an average week, 5.5 articles are published.
    What is MX:TAKN’s weekly average amount of articles?
    In an average week, 5.5 articles about MX:TAKN are published.
      What is MX:TAKN’s News Sentiment?
      100% of articles about MX:TAKN were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        BAYRYBayer
        ABTAbbott Laboratories
        INCYIncyte
        SMMTSummit Therapeutics
        CRVOCervoMed
        Showing the stocks with the most bullish news sentiment over the past week